Difference between revisions of "Team:CPU CHINA"

Line 165: Line 165:
  
  
<div id="words" style="position:relative;display:none;width:80%;top:53%;margin-left:10%;font-size:2.5rem;line-height:2.5;">
+
<div id="words" style="position:relative;display:none;width:80%;top:43%;margin-left:10%;font-size:2.5rem;line-height:2.5;">
 
<h1 style="position:relative;width:90%;margin-left:5%;top:28%;">A gene therapy strategy to target hepatocellular carcinoma based on conditional RNA interference</h1>
 
<h1 style="position:relative;width:90%;margin-left:5%;top:28%;">A gene therapy strategy to target hepatocellular carcinoma based on conditional RNA interference</h1>
 
   <h4 style="font-size:2.5rem;line-height:2.5">MicroRNA(miRNA) is a short non-coding RNA, which has the ability to target mRNA and medicate its degradation to downgrade gene expression at transcription level. This mediation effect is called post-transcriptional gene silencing (PTGS, which is also know as RNA interference). RNA interference(RNAi) has proved its potential as gene therapy. The mature miRNA are cleaved from pri-miRNA which gives us possibility to make it conditional. An “AND” gate system based on specific promoters and RNA-dependent RNA polymerase(RdRp) was designed to avoid undesirable effects due to low selectivity. Together, they formed our conditional RNA gene therapy. This year, CPU_CHINA is focusing on hepatocellular carcinoma (HCC). But significantly, the promoters and the target here can be replaced with other disease-specific promoters and target, in gene therapy for the corresponding diseases which enables our project to be a remarkable novel application.</h4>     
 
   <h4 style="font-size:2.5rem;line-height:2.5">MicroRNA(miRNA) is a short non-coding RNA, which has the ability to target mRNA and medicate its degradation to downgrade gene expression at transcription level. This mediation effect is called post-transcriptional gene silencing (PTGS, which is also know as RNA interference). RNA interference(RNAi) has proved its potential as gene therapy. The mature miRNA are cleaved from pri-miRNA which gives us possibility to make it conditional. An “AND” gate system based on specific promoters and RNA-dependent RNA polymerase(RdRp) was designed to avoid undesirable effects due to low selectivity. Together, they formed our conditional RNA gene therapy. This year, CPU_CHINA is focusing on hepatocellular carcinoma (HCC). But significantly, the promoters and the target here can be replaced with other disease-specific promoters and target, in gene therapy for the corresponding diseases which enables our project to be a remarkable novel application.</h4>     

Revision as of 16:15, 6 November 2018